UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.)



Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:		
	Preliminary Proxy Statement	
	Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2))	
	Definitive Proxy Statement	
	Definitive Additional Materials	
	Soliciting Material Pursuant to §240.14a-12	

ULTRAGENYX PHARMACEUTICAL INC.



(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

No fee required Fee paid previously with preliminary materials	Payment of Filing Fee (Check all boxes that apply):		
		No fee required	
		Fee paid previously with preliminary materials	
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11		Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11	



ULTRAGENYX PHARMACEUTICAL INC.

2024 Annual Meeting Vote by June 17, 2024 11:59 PM ET



V46232-P10936

ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT NOVATO, CA 94949

You invested in ULTRAGENYX PHARMACEUTICAL INC. and it's time to vote!

You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 18, 2024.

Get informed before you vote

View the Notice and Proxy Statement and Annual Report on Form 10-K for the year ended December 31, 2023 online OR you can receive a free paper or email copy of the material(s) by requesting prior to June 4, 2024. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.



*Please check the meeting materials for any special requirements for meeting attendance.

THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters.

Voting Items		
	Nominees:	
1a.	Deborah Dunsire, M.D.	Ser 🕑 For
1b.	Michael Narachi	Ser 🕑 For
1c.	Corsee D. Sanders, Ph.D.	Ser 🕑 For
2.	Approval of the Amended and Restated 2023 Incentive Plan.	Ser 🕑 For
3.	Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.	🕑 For
4.	Advisory (non-binding) vote to approve the compensation of our named executive officers.	Ser 🕑 For

Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Settings".

V46233-P10936